应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SYRE SPYRE THERAPEUTICS INC
休市中 12-05 16:00:00 EST
33.45
-0.06
-0.18%
盘后
33.45
+0.00
0.00%
17:52 EST
最高
34.06
最低
33.00
成交量
55.35万
今开
33.56
昨收
33.51
日振幅
3.16%
总市值
25.95亿
流通市值
21.35亿
总股本
7,759万
成交额
1,854万
换手率
0.87%
流通股本
6,383万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Spyre Therapeutics - Spy003显示约85天的半衰期,支持每季度或每年两次的维持剂量
美股速递 · 11-05
Spyre Therapeutics - Spy003显示约85天的半衰期,支持每季度或每年两次的维持剂量
Spyre Therapeutics:Spy003在所有剂量水平上耐受良好,安全性特征符合抗IL-23类药物
美股速递 · 11-05
Spyre Therapeutics:Spy003在所有剂量水平上耐受良好,安全性特征符合抗IL-23类药物
Spyre Therapeutics发布Spy003的积极中期I期结果,这是一种新型半衰期延长的抗IL-23抗体
美股速递 · 11-05
Spyre Therapeutics发布Spy003的积极中期I期结果,这是一种新型半衰期延长的抗IL-23抗体
SPYRE THERAPEUTICS INC预计截至2025年9月30日现金及等价物为4.862亿美元
美股速递 · 10-14
SPYRE THERAPEUTICS INC预计截至2025年9月30日现金及等价物为4.862亿美元
Spyre Therapeutics宣布授予员工股票期权激励奖励
投资观察 · 10-04
Spyre Therapeutics宣布授予员工股票期权激励奖励
Spyre Therapeutics在开创性2期Skyway篮式试验中为首位患者给药,Spy072成为首个在风湿性疾病中研究的抗Tl1a抗体
美股速递 · 09-15
Spyre Therapeutics在开创性2期Skyway篮式试验中为首位患者给药,Spy072成为首个在风湿性疾病中研究的抗Tl1a抗体
Spyre Therapeutics, Inc.2025财年第二财季实现净利润-36.72百万美元,同比减少37.27%
市场透视 · 08-11
Spyre Therapeutics, Inc.2025财年第二财季实现净利润-36.72百万美元,同比减少37.27%
Spyre Therapeutics, Inc.盘中异动 早盘股价大跌5.21%报18.48美元
市场透视 · 03-10
Spyre Therapeutics, Inc.盘中异动 早盘股价大跌5.21%报18.48美元
Spyre Therapeutics, Inc.2024财年实现净利润-1.50亿美元,同比减少58.09%
市场透视 · 03-09
Spyre Therapeutics, Inc.2024财年实现净利润-1.50亿美元,同比减少58.09%
异动解读 | Spyre Therapeutics Inc盘中大涨6.97%,新药研发取得重大进展
异动解读 · 03-05
异动解读 | Spyre Therapeutics Inc盘中大涨6.97%,新药研发取得重大进展
Spyre Therapeutics, Inc.盘中异动 股价大涨6.97%
市场透视 · 03-05
Spyre Therapeutics, Inc.盘中异动 股价大涨6.97%
Spyre Therapeutics, Inc.盘中异动 早盘快速上涨8.74%
市场透视 · 02-28
Spyre Therapeutics, Inc.盘中异动 早盘快速上涨8.74%
Spyre Therapeutics(SYRE.US):2024年Q4财报实现营收0美元,前值为0美元,预期值为233万美元;每股收益为-0.81美元,前值为-4.05美元,预期值为-0.97美元。
金融界 · 02-28
Spyre Therapeutics(SYRE.US):2024年Q4财报实现营收0美元,前值为0美元,预期值为233万美元;每股收益为-0.81美元,前值为-4.05美元,预期值为-0.97美元。
Spyre Therapeutics 2024年第四季度GAAP每股收益$(0.81) 优于$(1.01)的预期
财报速递 · 02-28
Spyre Therapeutics 2024年第四季度GAAP每股收益$(0.81) 优于$(1.01)的预期
Spyre Therapeutics, Inc.盘中异动 下午盘快速下跌5.40%
市场透视 · 02-27
Spyre Therapeutics, Inc.盘中异动 下午盘快速下跌5.40%
Spyre Therapeutics, Inc.盘中异动 急速跳水5.00%
市场透视 · 02-21
Spyre Therapeutics, Inc.盘中异动 急速跳水5.00%
Spyre Therapeutics, Inc.盘中异动 大幅跳水5.24%报21.72美元
市场透视 · 02-19
Spyre Therapeutics, Inc.盘中异动 大幅跳水5.24%报21.72美元
Spyre Therapeutics, Inc.盘中异动 早盘急速上涨5.07%
市场透视 · 01-31
Spyre Therapeutics, Inc.盘中异动 早盘急速上涨5.07%
Spyre Therapeutics, Inc.盘中异动 股价大涨5.00%
市场透视 · 01-27
Spyre Therapeutics, Inc.盘中异动 股价大涨5.00%
Spyre Therapeutics, Inc.盘中异动 早盘股价大涨5.33%
市场透视 · 01-21
Spyre Therapeutics, Inc.盘中异动 早盘股价大涨5.33%
加载更多
公司概况
公司名称:
SPYRE THERAPEUTICS INC
所属市场:
NASDAQ
上市日期:
--
主营业务:
Spyre Therapeutics, Inc.于2013年12月16日从特拉华州有限责任公司转换而来。该公司是一家生物技术公司,旨在通过结合同类最佳的抗体工程、合理的治疗组合以及用于患者选择的精准医疗方法,创造下一代炎症性肠病(IBD)产品。Spyre的产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。
发行价格:
--
{"stockData":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":33.45,"timestamp":1764968400000,"preClose":33.51,"halted":0,"volume":553532,"hourTrading":{"tag":"盘后","latestPrice":33.45,"preClose":33.45,"latestTime":"17:52 EST","volume":16961,"amount":567344.7,"timestamp":1764975145348},"delay":0,"floatShares":63829799,"shares":77592130,"eps":-2.003614,"marketStatus":"休市中","change":-0.06,"latestTime":"12-05 16:00:00 EST","open":33.56,"high":34.06,"low":33,"amount":18543237.309604,"amplitude":0.031632,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.003614,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":33.51,"preHourTrading":{"tag":"盘前","latestPrice":32.42,"preClose":33.51,"latestTime":"09:29 EST","volume":979,"amount":33061.998926,"timestamp":1764944973718},"postHourTrading":{"tag":"盘后","latestPrice":33.45,"preClose":33.45,"latestTime":"17:52 EST","volume":16961,"amount":567344.7,"timestamp":1764975145348},"volumeRatio":0.6397671034892896,"impliedVol":0.7972,"impliedVolPercentile":0.632},"requestUrl":"/m/hq/s/SYRE","defaultTab":"news","newsList":[{"id":"1177535994","title":"Spyre Therapeutics - Spy003显示约85天的半衰期,支持每季度或每年两次的维持剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1177535994","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177535994?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:40","pubTimestamp":1762292412,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics - Spy003显示约85天的半衰期,支持每季度或每年两次的维持剂量","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"1173012956","title":"Spyre Therapeutics:Spy003在所有剂量水平上耐受良好,安全性特征符合抗IL-23类药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1173012956","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173012956?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:40","pubTimestamp":1762292408,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics:Spy003在所有剂量水平上耐受良好,安全性特征符合抗IL-23类药物","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"1132251468","title":"Spyre Therapeutics发布Spy003的积极中期I期结果,这是一种新型半衰期延长的抗IL-23抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=1132251468","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132251468?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:02","pubTimestamp":1762290128,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics发布Spy003的积极中期I期结果,这是一种新型半衰期延长的抗IL-23抗体","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"1188563637","title":"SPYRE THERAPEUTICS INC预计截至2025年9月30日现金及等价物为4.862亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188563637","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188563637?lang=zh_cn&edition=full","pubTime":"2025-10-14 18:27","pubTimestamp":1760437631,"startTime":"0","endTime":"0","summary":"SPYRE THERAPEUTICS INC预计截至2025年9月30日现金及等价物为4.862亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"1195222682","title":"Spyre Therapeutics宣布授予员工股票期权激励奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1195222682","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195222682?lang=zh_cn&edition=full","pubTime":"2025-10-04 04:08","pubTimestamp":1759522131,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆,2025年10月3日——临床阶段生物技术公司Spyre Therapeutics, Inc.今日宣布,公司独立董事会薪酬委员会批准向三名非执行员工授予总计42,500股普通股的股票期权,作为根据经修订的《Spyre Therapeutics, Inc. 2018年股权激励计划》项下的股权激励奖励。Spyre Therapeutics是一家临床阶段生物技术公司,致力于通过结合一流的抗体工程、剂量优化和合理的治疗组合,开发下一代炎症性肠病和其他免疫介导疾病产品。Spyre的产品管线包括针对α4β7、TL1A和IL-23的研究性延长半衰期抗体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NQmain","BK4539","BK4139","IBD","BK4007","SYRE"],"gpt_icon":0},{"id":"1123290538","title":"Spyre Therapeutics在开创性2期Skyway篮式试验中为首位患者给药,Spy072成为首个在风湿性疾病中研究的抗Tl1a抗体","url":"https://stock-news.laohu8.com/highlight/detail?id=1123290538","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123290538?lang=zh_cn&edition=full","pubTime":"2025-09-15 20:05","pubTimestamp":1757937901,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics在开创性2期Skyway篮式试验中为首位患者给药,Spy072成为首个在风湿性疾病中研究的抗Tl1a抗体","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2558684897","title":"Spyre Therapeutics, Inc.2025财年第二财季实现净利润-36.72百万美元,同比减少37.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558684897","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558684897?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841699,"startTime":"0","endTime":"0","summary":"8月11日,Spyre Therapeutics, Inc.公布财报,公告显示公司2025财年第二财季净利润为-36.72百万美元,同比减少37.27%;其中营业收入为0.00美元,每股基本收益为-0.60美元。机构评级:截至2025年8月11日,当前有10家机构对Spyre Therapeutics, Inc.目标价做出预测,其中目标均价为53.90美元,其中最低目标价为21.00美元,最高目标价为71.00美元。Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程、合理的治疗组合和用于患者选择的精准医学方法来创造下一代炎症性肠病 产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000404a6de083c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000404a6de083c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ"],"gpt_icon":0},{"id":"2518327167","title":"Spyre Therapeutics, Inc.盘中异动 早盘股价大跌5.21%报18.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518327167","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518327167?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:36","pubTimestamp":1741617373,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时36分,Spyre Therapeutics, Inc.股票出现波动,股价大幅跳水5.21%。Spyre Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.02%。Spyre Therapeutics, Inc.公司简介:Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程,合理的治疗组合和精确的医学方法来为患者选择,创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223613abf314b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223613abf314b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SYRE"],"gpt_icon":0},{"id":"2518440864","title":"Spyre Therapeutics, Inc.2024财年实现净利润-1.50亿美元,同比减少58.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440864","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518440864?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449622,"startTime":"0","endTime":"0","summary":"3月9日,Spyre Therapeutics, Inc.公布财报,公告显示公司2024财年净利润为-1.50亿美元,同比减少58.09%;其中营业收入为0.00美元,每股基本收益为-3.18美元。从资产负债表来看,Spyre Therapeutics, Inc.总负债90.68百万美元,其中短期债务0.00美元,资产负债比为0.07,流动比率为0.12。机构评级:截至2025年3月9日,当前有8家机构对Spyre Therapeutics, Inc.目标价做出预测,其中目标均价为58.62美元,其中最低目标价为40.00美元,最高目标价为71.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000037abef96fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000037abef96fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"1196051233","title":"异动解读 | Spyre Therapeutics Inc盘中大涨6.97%,新药研发取得重大进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1196051233","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196051233?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:08","pubTimestamp":1741187300,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc作为一家专注于新型肠病药物研发的生物技术公司,周三盘中出现了6.97%的大涨行情,引发了市场的广泛关注。分析人士指出,SYRE股价大涨的原因可能与该公司最新研发进展有关。SYRE的这款新药主打免疫调节作用,与现有主流药物采用不同的治疗机理,预计上市后将给这一疾病领域带来全新的治疗选择。随着临床数据的持续披露,投资者对新药未来前景的信心不断增强,这也是推动SYRE股价持续走高的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Spyre Therapeutics Inc盘中大涨6.97%,新药研发取得重大进展","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SYRE"],"gpt_icon":0},{"id":"2517943943","title":"Spyre Therapeutics, Inc.盘中异动 股价大涨6.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943943","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517943943?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185121,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分,Spyre Therapeutics, Inc.股票出现异动,股价快速拉升6.97%。Spyre Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.21%。Spyre Therapeutics, Inc.公司简介:Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程,合理的治疗组合和精确的医学方法来为患者选择,创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223201963adc60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223201963adc60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","BK4139","LENZ"],"gpt_icon":0},{"id":"2514781803","title":"Spyre Therapeutics, Inc.盘中异动 早盘快速上涨8.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514781803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514781803?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753076,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分,Spyre Therapeutics, Inc.股票出现波动,股价快速拉升8.74%。Spyre Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.02%。Spyre Therapeutics, Inc.公司简介:Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程,合理的治疗组合和精确的医学方法来为患者选择,创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223116a25800d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223116a25800d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2514516354","title":"Spyre Therapeutics(SYRE.US):2024年Q4财报实现营收0美元,前值为0美元,预期值为233万美元;每股收益为-0.81美元,前值为-4.05美元,预期值为-0.97美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514516354","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514516354?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:08","pubTimestamp":1740697720,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics(SYRE.US):2024年Q4财报实现营收0美元,前值为0美元,预期值为233万美元;每股收益为-0.81美元,前值为-4.05美元,预期值为-0.97美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28070848442547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SYRE","LENZ"],"gpt_icon":0},{"id":"1141562432","title":"Spyre Therapeutics 2024年第四季度GAAP每股收益$(0.81) 优于$(1.01)的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1141562432","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141562432?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:46","pubTimestamp":1740692818,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics(LENZ) 2024年第四季度GAAP每股收益$(0.81),优于$(1.01)的预期以上内容来自Benzinga Earnings专栏,原文如下:Spyre $Therapeutics(LENZ)$ Q4 2024 GAAP EPS $(0.81) Beats $(1.01) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2514861925","title":"Spyre Therapeutics, Inc.盘中异动 下午盘快速下跌5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514861925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514861925?lang=zh_cn&edition=full","pubTime":"2025-02-27 03:14","pubTimestamp":1740597256,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时14分,Spyre Therapeutics, Inc.股票出现异动,股价急速下挫5.40%。Spyre Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.63%。Spyre Therapeutics, Inc.公司简介:Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程,合理的治疗组合和精确的医学方法来为患者选择,创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031417abde2ac4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031417abde2ac4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2513029974","title":"Spyre Therapeutics, Inc.盘中异动 急速跳水5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513029974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513029974?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:03","pubTimestamp":1740150200,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时03分,Spyre Therapeutics, Inc.股票出现波动,股价大幅下跌5.00%。Spyre Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.11%。Spyre Therapeutics, Inc.公司简介:Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程,合理的治疗组合和精确的医学方法来为患者选择,创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230321962b8308&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230321962b8308&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","SYRE"],"gpt_icon":0},{"id":"2512212196","title":"Spyre Therapeutics, Inc.盘中异动 大幅跳水5.24%报21.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512212196","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512212196?lang=zh_cn&edition=full","pubTime":"2025-02-19 03:20","pubTimestamp":1739906418,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日03时20分,Spyre Therapeutics, Inc.股票出现异动,股价快速下挫5.24%。Spyre Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.94%。Spyre Therapeutics, Inc.公司简介:Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程,合理的治疗组合和精确的医学方法来为患者选择,创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219032018abd3ea20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219032018abd3ea20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SYRE","BK4139"],"gpt_icon":0},{"id":"2507969624","title":"Spyre Therapeutics, Inc.盘中异动 早盘急速上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507969624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507969624?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:06","pubTimestamp":1738335969,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日23时06分,Spyre Therapeutics, Inc.股票出现异动,股价急速拉升5.07%。Spyre Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.07%。Spyre Therapeutics, Inc.公司简介:Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程,合理的治疗组合和精确的医学方法来为患者选择,创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312306099614ef73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312306099614ef73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2506416303","title":"Spyre Therapeutics, Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506416303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506416303?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:51","pubTimestamp":1737989486,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时51分,Spyre Therapeutics, Inc.股票出现异动,股价快速拉升5.00%。Spyre Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.11%。Spyre Therapeutics, Inc.公司简介:Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程,合理的治疗组合和精确的医学方法来为患者选择,创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225126a2316f11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225126a2316f11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2505226271","title":"Spyre Therapeutics, Inc.盘中异动 早盘股价大涨5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505226271","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505226271?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:34","pubTimestamp":1737470099,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时34分,Spyre Therapeutics, Inc.股票出现波动,股价快速拉升5.33%。Spyre Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.88%。Spyre Therapeutics, Inc.公司简介:Spyre Therapeutics Inc 是一家生物技术公司,旨在通过结合抗体工程,合理的治疗组合和精确的医学方法来为患者选择,创造下一代炎症性肠病产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223459abb347af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223459abb347af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SYRE","BK4139","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.spyre.com","stockEarnings":[{"period":"1week","weight":0.115},{"period":"1month","weight":0.4639},{"period":"3month","weight":0.9676},{"period":"6month","weight":0.9711},{"period":"1year","weight":0.3092},{"period":"ytd","weight":0.4369}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Spyre Therapeutics, Inc.于2013年12月16日从特拉华州有限责任公司转换而来。该公司是一家生物技术公司,旨在通过结合同类最佳的抗体工程、合理的治疗组合以及用于患者选择的精准医疗方法,创造下一代炎症性肠病(IBD)产品。Spyre的产品线包括针对α4β7、TL1A和IL-23的延长半衰期抗体。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.041871},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.006198},{"month":3,"riseRate":0.444444,"avgChangeRate":0.005514},{"month":4,"riseRate":0.111111,"avgChangeRate":-0.063951},{"month":5,"riseRate":0.5,"avgChangeRate":-0.058711},{"month":6,"riseRate":0.4,"avgChangeRate":0.119173},{"month":7,"riseRate":0.4,"avgChangeRate":-0.002229},{"month":8,"riseRate":0.8,"avgChangeRate":0.108946},{"month":9,"riseRate":0.6,"avgChangeRate":0.016514},{"month":10,"riseRate":0.4,"avgChangeRate":0.109394},{"month":11,"riseRate":0.4,"avgChangeRate":0.005048},{"month":12,"riseRate":0.4,"avgChangeRate":-0.017116}],"exchange":"NASDAQ","name":"SPYRE THERAPEUTICS INC","nameEN":"SPYRE THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SPYRE THERAPEUTICS INC,SYRE,SPYRE THERAPEUTICS INC股票,SPYRE THERAPEUTICS INC股票老虎,SPYRE THERAPEUTICS INC股票老虎国际,SPYRE THERAPEUTICS INC行情,SPYRE THERAPEUTICS INC股票行情,SPYRE THERAPEUTICS INC股价,SPYRE THERAPEUTICS INC股市,SPYRE THERAPEUTICS INC股票价格,SPYRE THERAPEUTICS INC股票交易,SPYRE THERAPEUTICS INC股票购买,SPYRE THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SPYRE THERAPEUTICS INC(SYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SPYRE THERAPEUTICS INC(SYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}